Brief: NeuroSense Receives FDA Clearance To Initiate Pivotal Phase 3 Trial For PrimeC In ALS

Neurosense Therapeutics

24/11/2025 18:28

Nov 24 (Reuters) - NeuroSense Therapeutics Ltd NRSN.O:

NEUROSENSE RECEIVES FDA CLEARANCE TO INITIATE PIVOTAL PHASE 3 TRIAL FOR PRIMEC IN ALS

Source text: ID:nPn8V4WZ0a

Further company coverage: NRSN.O

 ((Reuters.Briefs@thomsonreuters.com;))